patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_407630 | REC_0016901 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 27 | 5.7 | 90 | female | 2 | 19 | 7.2 | 1 | pembrolizumab 200 mg q3w | 34.9 | true | MSS | 2026-03-15T05:36:01.939632+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511808 | REC_0016902 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 12.1 | 72 | female | 2 | 15 | 6.7 | 7 | osimertinib 80 mg daily | 7.7 | true | MSI-H | 2026-03-15T05:36:01.940066+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346508 | REC_0016903 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 11.9 | 56 | female | 0 | 16 | 5.5 | 7 | sotorasib 960 mg daily | 7.7 | false | MSS | 2026-03-15T05:36:01.940548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_995685 | REC_0016904 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 9 | 58 | female | 1 | 12 | 6.1 | 1 | alectinib 600 mg BID | 18 | true | MSS | 2026-03-15T05:36:01.940927+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885041 | REC_0016905 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 13.2 | 69 | male | 0 | 0 | 5.8 | 3 | alectinib 600 mg BID | 7.7 | true | MSI-H | 2026-03-15T05:36:01.941307+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344842 | REC_0016906 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 13.4 | 61 | female | 1 | 11 | 7.1 | 5 | sotorasib 960 mg daily | 4 | false | MSI-H | 2026-03-15T05:36:01.941668+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322002 | REC_0016907 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 27 | 11.3 | 78 | female | 1 | 28 | 5.5 | 0 | alectinib 600 mg BID | 40.9 | false | MSI-H | 2026-03-15T05:36:01.942026+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_362228 | REC_0016908 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 8.1 | 83 | female | 1 | 11 | 5.8 | 7 | entrectinib 600 mg daily | 7.3 | false | MSS | 2026-03-15T05:36:01.942377+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_836624 | REC_0016909 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 11.4 | 70 | female | 1 | 20 | 4.3 | 2 | osimertinib 80 mg daily | 25.3 | true | MSI-H | 2026-03-15T05:36:01.942719+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_490203 | REC_0016910 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5.4 | 73 | female | 1 | 41 | 3.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.9 | true | MSS | 2026-03-15T05:36:01.943055+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646232 | REC_0016911 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 16.5 | 71 | female | 2 | 25 | 3.1 | 4 | sotorasib 960 mg daily | 9 | true | MSI-H | 2026-03-15T05:36:01.943421+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306609 | REC_0016912 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 16.6 | 72 | female | 2 | 14 | 5.8 | 5 | osimertinib 80 mg daily | 9.1 | true | MSI-H | 2026-03-15T05:36:01.943771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824126 | REC_0016913 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 7.5 | 73 | male | 1 | 10 | 4.9 | 2 | osimertinib 80 mg daily | 16.3 | false | MSS | 2026-03-15T05:36:01.944280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317117 | REC_0016914 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 37 | 13.2 | 60 | male | 1 | 11 | 6.1 | 6 | osimertinib 80 mg daily | 14.2 | true | MSS | 2026-03-15T05:36:01.944869+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963594 | REC_0016915 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 16.4 | 58 | female | 0 | 18 | 8.4 | 4 | osimertinib 80 mg daily | 6.7 | true | MSS | 2026-03-15T05:36:01.945285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998749 | REC_0016916 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 9 | 75 | female | 2 | 54 | 5.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.2 | true | MSS | 2026-03-15T05:36:01.945629+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755664 | REC_0016917 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 4.9 | 73 | male | 2 | 7 | 4.4 | 2 | pembrolizumab 200 mg q3w | 21.4 | true | MSS | 2026-03-15T05:36:01.945988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_856316 | REC_0016918 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 16.1 | 47 | female | 0 | 13 | 5.2 | 5 | sotorasib 960 mg daily | 12.3 | false | MSS | 2026-03-15T05:36:01.946365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406740 | REC_0016919 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 4.9 | 68 | male | 0 | 60 | 5.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 10.6 | false | MSS | 2026-03-15T05:36:01.946742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_581099 | REC_0016920 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 4.3 | 83 | female | 1 | 54 | 4.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.3 | true | MSS | 2026-03-15T05:36:01.947102+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_369643 | REC_0016921 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 27 | 8.6 | 73 | female | 2 | 12 | 6.7 | 0 | osimertinib 80 mg daily | 52.2 | true | MSS | 2026-03-15T05:36:01.947468+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_694049 | REC_0016922 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 9.3 | 65 | male | 1 | 51 | 7.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 10.4 | true | MSS | 2026-03-15T05:36:01.947841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_200441 | REC_0016923 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 28 | 16.1 | 79 | female | 1 | 14 | 3.5 | 0 | entrectinib 600 mg daily | 11.9 | false | MSS | 2026-03-15T05:36:01.948375+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_146083 | REC_0016924 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 16.1 | 67 | female | 0 | 26 | 4.5 | 6 | entrectinib 600 mg daily | 15.2 | false | MSI-H | 2026-03-15T05:36:01.948804+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_701405 | REC_0016925 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 7 | 73 | male | 1 | 16 | 4.2 | 5 | pembrolizumab 200 mg q3w | 11.3 | true | MSS | 2026-03-15T05:36:01.949196+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_496398 | REC_0016926 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 7.8 | 71 | female | 1 | 12 | 3.3 | 3 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:36:01.949596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_443444 | REC_0016927 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 6.1 | 51 | female | 0 | 12 | 5.9 | 8 | entrectinib 600 mg daily | 17.7 | false | MSS | 2026-03-15T05:36:01.950202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267571 | REC_0016928 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 10.5 | 48 | male | 0 | 13 | 3.2 | 5 | osimertinib 80 mg daily | 6.6 | true | MSS | 2026-03-15T05:36:01.950662+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_802147 | REC_0016929 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 6.7 | 53 | female | 0 | 11 | 3 | 1 | sotorasib 960 mg daily | 17 | false | MSS | 2026-03-15T05:36:01.951007+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_633140 | REC_0016930 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 15.7 | 56 | male | 1 | 21 | 4.6 | 8 | alectinib 600 mg BID | 8.4 | false | MSI-H | 2026-03-15T05:36:01.951350+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397898 | REC_0016931 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 14.9 | 79 | female | 1 | 15 | 5 | 2 | osimertinib 80 mg daily | 6.7 | false | MSI-H | 2026-03-15T05:36:01.951705+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720270 | REC_0016932 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 14.9 | 55 | female | 0 | 21 | 5 | 3 | entrectinib 600 mg daily | 4 | false | MSI-H | 2026-03-15T05:36:01.952069+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507342 | REC_0016933 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 7.9 | 74 | female | 1 | 3 | 4 | 2 | entrectinib 600 mg daily | 19.5 | true | MSS | 2026-03-15T05:36:01.952500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_188811 | REC_0016934 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 10.9 | 69 | female | 0 | 10 | 6.8 | 6 | sotorasib 960 mg daily | 17.6 | true | MSS | 2026-03-15T05:36:01.952885+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_666842 | REC_0016935 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 9.9 | 62 | female | 1 | 17 | 6.3 | 7 | osimertinib 80 mg daily | 13.6 | true | MSS | 2026-03-15T05:36:01.953278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109317 | REC_0016936 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 7.7 | 64 | female | 0 | 16 | 5.1 | 6 | alectinib 600 mg BID | 13.1 | false | MSS | 2026-03-15T05:36:01.953661+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_592805 | REC_0016937 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 15 | 14.1 | 65 | male | 1 | 7 | 4.8 | 2 | osimertinib 80 mg daily | 29.9 | true | MSS | 2026-03-15T05:36:01.954042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_663408 | REC_0016938 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 14.3 | 83 | male | 1 | 24 | 5.5 | 6 | alectinib 600 mg BID | 15 | true | MSI-H | 2026-03-15T05:36:01.954395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_773976 | REC_0016939 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 12 | 10.3 | 76 | female | 1 | 13 | 5.1 | 2 | osimertinib 80 mg daily | 14.4 | false | MSI-H | 2026-03-15T05:36:01.954723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_658816 | REC_0016940 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 8.4 | 71 | female | 1 | 20 | 6.8 | 1 | entrectinib 600 mg daily | 23.1 | true | MSS | 2026-03-15T05:36:01.955308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_597591 | REC_0016941 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 6.4 | 50 | male | 0 | 22 | 6.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.6 | true | MSS | 2026-03-15T05:36:01.955692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_618565 | REC_0016942 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 9.3 | 69 | female | 1 | 11 | 5.5 | 2 | alectinib 600 mg BID | 17.8 | true | MSS | 2026-03-15T05:36:01.956032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_289023 | REC_0016943 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 32 | 6.2 | 58 | female | 0 | 18 | 4.7 | 5 | pembrolizumab 200 mg q3w | 10.6 | true | MSS | 2026-03-15T05:36:01.956537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963836 | REC_0016944 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 34 | 13.7 | 66 | female | 0 | 8 | 5.7 | 1 | sotorasib 960 mg daily | 6 | false | MSI-H | 2026-03-15T05:36:01.956934+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991275 | REC_0016945 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 13.1 | 51 | male | 0 | 14 | 4.8 | 6 | entrectinib 600 mg daily | 10.9 | true | MSS | 2026-03-15T05:36:01.957356+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_521787 | REC_0016946 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 16 | 5.4 | 63 | female | 0 | 8 | 9.3 | 2 | pembrolizumab 200 mg q3w | 22.4 | true | MSS | 2026-03-15T05:36:01.957725+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623814 | REC_0016947 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 5.7 | 83 | female | 1 | 22 | 7.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.5 | false | MSS | 2026-03-15T05:36:01.958111+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_716826 | REC_0016948 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 12.6 | 62 | female | 0 | 12 | 5.2 | 6 | osimertinib 80 mg daily | 15.2 | false | MSI-H | 2026-03-15T05:36:01.958543+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_840344 | REC_0016949 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 5.3 | 55 | male | 1 | 20 | 6.9 | 4 | osimertinib 80 mg daily | 16.9 | false | MSS | 2026-03-15T05:36:01.959024+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584086 | REC_0016950 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 8.1 | 63 | female | 0 | 7 | 4 | 2 | entrectinib 600 mg daily | 14.2 | true | MSS | 2026-03-15T05:36:01.959477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_179308 | REC_0016951 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 15.5 | 62 | female | 0 | 16 | 7.2 | 2 | osimertinib 80 mg daily | 19.4 | false | MSI-H | 2026-03-15T05:36:01.959871+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448091 | REC_0016952 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 7.5 | 60 | female | 1 | 11 | 7.4 | 1 | osimertinib 80 mg daily | 31.8 | false | MSS | 2026-03-15T05:36:01.960278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_680218 | REC_0016953 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 5.8 | 70 | female | 2 | 42 | 4.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.7 | false | MSS | 2026-03-15T05:36:01.960946+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_777412 | REC_0016954 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 15.3 | 72 | female | 1 | 14 | 6.1 | 5 | entrectinib 600 mg daily | 10.5 | false | MSI-H | 2026-03-15T05:36:01.961457+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_746105 | REC_0016955 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 25 | 3.7 | 76 | female | 3 | 37 | 4 | 0 | carboplatin + paclitaxel + pembrolizumab | 13.2 | false | MSS | 2026-03-15T05:36:01.961847+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_472062 | REC_0016956 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 35 | 6.2 | 61 | female | 1 | 17 | 5 | 4 | sotorasib 960 mg daily | 10 | false | MSS | 2026-03-15T05:36:01.962248+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843551 | REC_0016957 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7.3 | 53 | female | 0 | 56 | 5.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.5 | true | MSS | 2026-03-15T05:36:01.962635+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535101 | REC_0016958 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 7.8 | 55 | female | 0 | 13 | 6.5 | 5 | osimertinib 80 mg daily | 19.9 | false | MSS | 2026-03-15T05:36:01.962975+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_995001 | REC_0016959 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 16 | 13.7 | 60 | female | 1 | 9 | 4.5 | 7 | sotorasib 960 mg daily | 14.3 | true | MSI-H | 2026-03-15T05:36:01.963289+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_542486 | REC_0016960 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 25 | 9.8 | 86 | female | 0 | 5 | 7.3 | 0 | alectinib 600 mg BID | 18.3 | true | MSS | 2026-03-15T05:36:01.963586+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132439 | REC_0016961 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 11.7 | 66 | female | 0 | 28 | 4.2 | 4 | osimertinib 80 mg daily | 6.8 | true | MSI-H | 2026-03-15T05:36:01.963896+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860896 | REC_0016962 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 20 | 17.3 | 66 | male | 0 | 22 | 4.7 | 0 | osimertinib 80 mg daily | 17.7 | false | MSI-H | 2026-03-15T05:36:01.964376+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_298765 | REC_0016963 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 16 | 74 | male | 3 | 16 | 4.4 | 2 | entrectinib 600 mg daily | 23.8 | true | MSS | 2026-03-15T05:36:01.964802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116561 | REC_0016964 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 33 | 7.3 | 60 | male | 1 | 9 | 4.9 | 2 | alectinib 600 mg BID | 19.7 | true | MSS | 2026-03-15T05:36:01.965201+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_238422 | REC_0016965 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 7.8 | 82 | male | 2 | 54 | 7.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.9 | true | MSS | 2026-03-15T05:36:01.965603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871953 | REC_0016966 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 10.3 | 68 | female | 1 | 20 | 4.5 | 4 | entrectinib 600 mg daily | 9.8 | false | MSI-H | 2026-03-15T05:36:01.966178+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449544 | REC_0016967 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 11.8 | 62 | female | 0 | 23 | 5.6 | 0 | entrectinib 600 mg daily | 24.5 | false | MSI-H | 2026-03-15T05:36:01.966649+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_158833 | REC_0016968 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 11.3 | 53 | male | 0 | 21 | 4.9 | 5 | osimertinib 80 mg daily | 12 | false | MSS | 2026-03-15T05:36:01.967125+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371074 | REC_0016969 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 15.7 | 60 | female | 1 | 10 | 5 | 4 | alectinib 600 mg BID | 8.2 | false | MSI-H | 2026-03-15T05:36:01.967513+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932421 | REC_0016970 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 13.5 | 61 | female | 0 | 19 | 8.6 | 2 | osimertinib 80 mg daily | 13.2 | false | MSI-H | 2026-03-15T05:36:01.967865+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323433 | REC_0016971 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 11.5 | 67 | female | 1 | 13 | 3.9 | 1 | pembrolizumab 200 mg q3w | 22.9 | true | MSS | 2026-03-15T05:36:01.968398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731626 | REC_0016972 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 16 | 61 | female | 1 | 20 | 6.3 | 1 | osimertinib 80 mg daily | 14.3 | false | MSS | 2026-03-15T05:36:01.968829+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511738 | REC_0016973 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 15 | 14.5 | 55 | female | 0 | 10 | 5 | 1 | sotorasib 960 mg daily | 19.6 | false | MSI-H | 2026-03-15T05:36:01.969226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_494002 | REC_0016974 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 9.9 | 77 | female | 1 | 19 | 4.8 | 4 | osimertinib 80 mg daily | 12.8 | true | MSS | 2026-03-15T05:36:01.969630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_330628 | REC_0016975 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 1.6 | 76 | male | 2 | 74 | 5.3 | 4 | pembrolizumab 200 mg q3w | 8.8 | true | MSS | 2026-03-15T05:36:01.969990+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864279 | REC_0016976 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 8.5 | 75 | female | 1 | 27 | 6.6 | 0 | osimertinib 80 mg daily | 24.7 | false | MSS | 2026-03-15T05:36:01.970341+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_910871 | REC_0016977 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 12.9 | 77 | female | 1 | 6 | 6.1 | 7 | entrectinib 600 mg daily | 10.5 | true | MSI-H | 2026-03-15T05:36:01.970665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_327663 | REC_0016978 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 17.8 | 63 | male | 0 | 17 | 6.1 | 8 | osimertinib 80 mg daily | 9.7 | false | MSI-H | 2026-03-15T05:36:01.971015+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_806849 | REC_0016979 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 13.9 | 67 | female | 0 | 10 | 4.1 | 4 | alectinib 600 mg BID | 9.6 | false | MSS | 2026-03-15T05:36:01.971545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_365704 | REC_0016980 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 26 | 5.5 | 68 | female | 0 | 42 | 6.4 | 0 | carboplatin + paclitaxel + pembrolizumab | 39.4 | true | MSS | 2026-03-15T05:36:01.971955+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_198769 | REC_0016981 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 10.2 | 71 | female | 1 | 8 | 6.5 | 5 | pembrolizumab 200 mg q3w | 9.6 | false | MSI-H | 2026-03-15T05:36:01.972452+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105273 | REC_0016982 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 11.5 | 63 | male | 0 | 20 | 7.1 | 3 | entrectinib 600 mg daily | 6.5 | true | MSS | 2026-03-15T05:36:01.972841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462059 | REC_0016983 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 11.9 | 60 | female | 1 | 19 | 5.7 | 6 | alectinib 600 mg BID | 16.3 | false | MSI-H | 2026-03-15T05:36:01.973235+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214013 | REC_0016984 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 14.2 | 54 | male | 0 | 13 | 5.8 | 5 | sotorasib 960 mg daily | 11.8 | true | MSI-H | 2026-03-15T05:36:01.973602+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790920 | REC_0016985 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 2.2 | 66 | female | 0 | 45 | 6.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 21.1 | false | MSS | 2026-03-15T05:36:01.973926+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_191133 | REC_0016986 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 17.5 | 64 | female | 1 | 13 | 6.5 | 1 | entrectinib 600 mg daily | 22.1 | false | MSS | 2026-03-15T05:36:01.974205+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960778 | REC_0016987 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 5.3 | 70 | female | 2 | 43 | 6.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 29.7 | false | MSS | 2026-03-15T05:36:01.974480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_575916 | REC_0016988 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 10.8 | 57 | male | 0 | 5 | 5 | 4 | osimertinib 80 mg daily | 18.6 | true | MSI-H | 2026-03-15T05:36:01.974787+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_964618 | REC_0016989 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 6.1 | 72 | female | 1 | 32 | 6 | 0 | carboplatin + paclitaxel + pembrolizumab | 23.2 | false | MSS | 2026-03-15T05:36:01.975079+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650596 | REC_0016990 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 18.6 | 59 | female | 1 | 12 | 5.5 | 8 | osimertinib 80 mg daily | 13.3 | false | MSI-H | 2026-03-15T05:36:01.975388+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_486307 | REC_0016991 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 11.9 | 59 | male | 1 | 13 | 7.3 | 1 | entrectinib 600 mg daily | 26.1 | false | MSI-H | 2026-03-15T05:36:01.975742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_335331 | REC_0016992 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 12.8 | 58 | male | 1 | 10 | 6.6 | 5 | osimertinib 80 mg daily | 10.9 | true | MSI-H | 2026-03-15T05:36:01.976494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676063 | REC_0016993 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 32 | 6 | 60 | male | 0 | 73 | 5.6 | 0 | pembrolizumab 200 mg q3w | 41.9 | false | MSS | 2026-03-15T05:36:01.976917+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_190175 | REC_0016994 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 33 | 10.4 | 63 | female | 0 | 21 | 4.4 | 1 | alectinib 600 mg BID | 26.1 | true | MSS | 2026-03-15T05:36:01.977321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_341786 | REC_0016995 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 21 | 7.2 | 72 | female | 0 | 32 | 6.4 | 1 | pembrolizumab 200 mg q3w | 15.4 | false | MSS | 2026-03-15T05:36:01.977696+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_226931 | REC_0016996 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 19 | 4.8 | 72 | female | 3 | 53 | 6.3 | 2 | pembrolizumab 200 mg q3w | 19.4 | true | MSS | 2026-03-15T05:36:01.978064+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_392345 | REC_0016997 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 8.7 | 78 | female | 2 | 18 | 4.1 | 6 | sotorasib 960 mg daily | 10.2 | false | MSS | 2026-03-15T05:36:01.978397+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_175307 | REC_0016998 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 10.4 | 62 | female | 1 | 17 | 4.7 | 7 | osimertinib 80 mg daily | 12 | true | MSS | 2026-03-15T05:36:01.978697+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_152767 | REC_0016999 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 16 | 8.1 | 74 | female | 3 | 21 | 5.4 | 1 | sotorasib 960 mg daily | 19 | false | MSS | 2026-03-15T05:36:01.979039+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_985890 | REC_0017000 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 5.4 | 57 | male | 0 | 21 | 4.3 | 6 | pembrolizumab 200 mg q3w | 11.9 | true | MSS | 2026-03-15T05:36:01.979404+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.